We believe Perrigo is in fine financial health. At the end of 2024, the company had roughly $560 million in cash and equivalents with about $3.3 billion in long-term debt. Its balance sheet was in a ...

JNJ jumps over 6% on Q2 earnings beat and full-year guidance increase, driven by strong pharma sales and improved MedTech ...